Medigen Vaccine Biologics (TWSE:4162)

Executive Summary

Medigen Vaccine Biologics Corp is a Taiwan-based commercial-stage vaccine company focused on inactivated viral vaccines for pediatric infectious diseases. Its flagship product, an Enterovirus A71 (EV71) vaccine, has received approvals in Taiwan and Vietnam, leveraging aluminum-phosphate adjuvant technology to induce durable immunity in infants and young children. The company is publicly traded on the Taiwan Stock Exchange (TWSE:4162) and maintains a manufacturing facility in Taipei. With a strong foothold in the Asian vaccine market, Medigen is positioned to address unmet needs in childhood infectious diseases, though its pipeline beyond the EV71 vaccine remains limited. The company's commercial revenue from the EV71 vaccine provides a foundation for future growth, but expansion into new markets and indications will be critical for long-term value creation.

Upcoming Catalysts (preview)

• Q2 2026Regulatory approval of EV71 vaccine in additional Southeast Asian countries80% success
• Q4 2026Initiation of clinical trials for a next-generation multivalent pediatric vaccine50% success
• H2 2026Potential partnership or licensing deal for EV71 vaccine in China60% success